CN1752088A - 含有替莫唑胺酯的药用组合物 - Google Patents
含有替莫唑胺酯的药用组合物 Download PDFInfo
- Publication number
- CN1752088A CN1752088A CNA2004100720564A CN200410072056A CN1752088A CN 1752088 A CN1752088 A CN 1752088A CN A2004100720564 A CNA2004100720564 A CN A2004100720564A CN 200410072056 A CN200410072056 A CN 200410072056A CN 1752088 A CN1752088 A CN 1752088A
- Authority
- CN
- China
- Prior art keywords
- methyl
- imidazolo
- oxo
- ester
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 150000002148 esters Chemical class 0.000 title claims description 90
- 239000003814 drug Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 5
- -1 substituted-phenyl Chemical group 0.000 claims description 81
- 238000002360 preparation method Methods 0.000 claims description 50
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 24
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- 239000004698 Polyethylene Substances 0.000 claims description 16
- 229920000573 polyethylene Polymers 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 15
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 15
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 15
- 239000005642 Oleic acid Substances 0.000 claims description 15
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 15
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 15
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 13
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 13
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 13
- 239000004530 micro-emulsion Substances 0.000 claims description 13
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 238000007872 degassing Methods 0.000 claims description 12
- 150000004702 methyl esters Chemical class 0.000 claims description 12
- 229920001296 polysiloxane Polymers 0.000 claims description 12
- 238000004321 preservation Methods 0.000 claims description 12
- 239000004215 Carbon black (E152) Substances 0.000 claims description 10
- 229930195733 hydrocarbon Natural products 0.000 claims description 10
- 150000002430 hydrocarbons Chemical class 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 7
- 239000004800 polyvinyl chloride Substances 0.000 claims description 7
- ZTVIKZXZYLEVOL-DGKWVBSXSA-N 2-hydroxy-2-phenylacetic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical group C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-DGKWVBSXSA-N 0.000 claims description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 6
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 239000010695 polyglycol Substances 0.000 claims description 4
- 229920000151 polyglycol Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229920000742 Cotton Polymers 0.000 claims description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 2
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004166 Lanolin Substances 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000010977 jade Substances 0.000 claims description 2
- 235000019388 lanolin Nutrition 0.000 claims description 2
- 229940039717 lanolin Drugs 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920006264 polyurethane film Polymers 0.000 claims description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 229940099259 vaseline Drugs 0.000 claims description 2
- 210000002268 wool Anatomy 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 1
- 229960003711 glyceryl trinitrate Drugs 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 21
- 229940079593 drug Drugs 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 15
- 229960004964 temozolomide Drugs 0.000 description 14
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 12
- 238000001819 mass spectrum Methods 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- VVTMIOYTNALQAW-UHFFFAOYSA-N 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid Chemical compound O=C1N(C)N=NC2=C(C(O)=O)N=CN21 VVTMIOYTNALQAW-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 229960001681 croscarmellose sodium Drugs 0.000 description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 201000008261 skin carcinoma Diseases 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- CVHXQHIJOULCNQ-UHFFFAOYSA-N 1,3-dinitrooxypropan-2-yl nitrate;1-nitropropane-1,2,3-triol Chemical compound OCC(O)C(O)[N+]([O-])=O.[O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O CVHXQHIJOULCNQ-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DCKVNWZUADLDEH-RXMQYKEDSA-N [(2r)-butan-2-yl] acetate Chemical compound CC[C@@H](C)OC(C)=O DCKVNWZUADLDEH-RXMQYKEDSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940081995 fluorouracil injection Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940072981 nitro-dur Drugs 0.000 description 1
- 229940072992 nitrodisc Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
本发明公开以替莫唑胺-8-羧酸正己酯为代表的一系列替莫唑胺-8-羧酸酯,抑制癌细胞活性和抑制小鼠体内癌块生长的活性,以及它们在制备抗癌制剂中的应用。本发明还公开了含有这种化合物的组合物,及其制备方法。
Description
技术领域
本发明涉及医药领域,具体涉及替莫唑胺-8-羧酸酯的系列衍生物,及该系列衍生物透皮吸收治疗皮肤癌制剂中的应用,和以之为活性成分的药物组合物。
背景技术
替莫唑胺为一种烷化剂型抗癌药物,具有广谱抗肿瘤活性[L.H.Tsang,et al.CancerChemother Pharmacol.27(1991):342-346],尤其是对神经胶质瘤(脑癌)和黑色素瘤(皮肤癌)。替莫唑胺的胶囊剂已在欧美批准用于治疗恶性神经胶质瘤。WO 00/57867描述了一个周期给药方式。替莫唑胺的胶囊剂在我国也已批准临床。II期临床结果显示替莫唑胺对恶性黑色素瘤有效[N.M.Bleehen,et al.J.Clin.Oncol.13(1995):910-913]。近期的III期临床结果显示替莫唑胺治疗恶性黑色素瘤疗效与达卡巴嗪相同[M.R.Middleton,et al.J.Clin.Oncol.18(2000):158-166],同时显示服用替莫唑胺产生的副反应与达卡巴嗪副反应相似,如:白细胞减少、恶心、呕吐、脱发、红疹及便秘。此外口服替莫唑胺显示剂量限制的骨髓毒性[A.M.Heimberger,et al.Clin.Can.Res.6(2000):4148-4153].在以往剂型改变研究中证明替莫唑胺溶液腱鞘注射剂型可以降低副反应[J.H.Sampson,et al.Can.Res.5(1999):1183-11886]。因此替莫唑胺透皮制剂应该是用于治疗皮肤癌的理想剂型,尤其是在早期。已有研究证明托瑞米芬局部给药在肿瘤部位产生高的局部浓度,而系统药物浓度很低[L.Soe,et al.Cancer Chemother.Pharmacol.,39(1997):513-520],因此产生低的系统毒性。
皮肤给药通常受到皮肤屏障及药物理化性质的制约。我们研究证明(WO 00/57867)替莫唑胺不能通过人造皮肤(硅膜)、大鼠皮肤和人皮肤,不能直接制成透皮制剂。因此,替莫唑胺的应用范围受到一定的限制。
以往对替莫唑胺结构改造和衍生物的合成都集中在三位氮上的取代基的替换和八酰胺基氮上的取代基的改变。EP0252682(1987)的通式结构中要求了替莫唑胺-8-羧酸甲,乙,丙,丁酯,但并没有公开其药理作用,同时也没有暗示其作为药用的可能。
发明内容
本发明目的在于提供一种替莫唑胺-8-羧酸酯和-8-酰胺的系列化合物及其制备方法。
本发明的另一目的在于提供了该系列化合物抗皮肤癌的作用。
本发明的又一目的在于提供了一种以该系列化合物为活性成分的药用组合物及其制备方法。
本发明所述的替莫唑胺-8-羧酸酯的结构如下同时所示:
其中X可以是O和S;
R可以是C3~C10的直链饱和烃基,可以是C3~C10的支链饱和烃基,可以是C3~C10的不饱和烯基,可以是C3~C10的不饱和炔基;
R可以是取代的上述直链的饱和烃,支链的饱和烃,不饱和烃,取代基可以是烃氧基,烃巯基,烃胺基,苯基,取代苯基。
R优选为甲基、乙基、丙基、异丙基、正丁基、1-甲基-丙基、2-甲基-丙基、戊基、1-甲基-丁基、2-甲基-丁基、3-甲基-丁基、己基、1-甲基-戊基、2-甲基-戊基、3-甲基-戊基、4-甲基-戊基、庚基、1-甲基-己基、2-甲基-己基、3-甲基-己基、4-甲基-己基、5-甲基-己基、辛基、1-甲基-庚基、2-甲基-庚基、3-甲基-庚基、4-甲基-庚基、5-甲基-庚基、6-甲基-庚基、1-乙基-丙基、1-乙基-丁基、1-乙基-戊基、2-乙基-戊基、3-乙基-戊基。
上述取代基的衍生物优选为替莫唑胺-8-羧酸甲酯、替莫唑胺-8-羧酸乙酯、替莫唑胺-8-羧酸丙酯、替莫唑胺-8-羧酸丁酯、替莫唑胺-8-羧酸-1-甲基-丁酯、替莫唑胺-8-羧酸-1-乙基-丁酯、替莫唑胺-8-羧酸-1-乙基-丙酯、替莫唑胺-8-羧酸-1-乙基-戊酯、替莫唑胺-8-羧酸-1-甲基-己酯、替莫唑胺-8-羧酸-1-甲基-己酯、替莫唑胺-8-羧酸-2-甲基-己酯、替莫唑胺-8-羧酸-3-甲基-己酯、替莫唑胺-8-羧酸-4-甲基-己酯、替莫唑胺-8-羧酸-5-甲基-己酯、替莫唑胺-8-羧酸-1-甲基-庚酯、替莫唑胺-8-羧酸-2-甲基-庚酯、替莫唑胺-8-羧酸-3-甲基-庚酯、替莫唑胺-8-羧酸-4-甲基-庚酯、替莫唑胺-8-羧酸-5-甲基-庚酯、替莫唑胺-8-羧酸-6-甲基-庚酯、替莫唑胺-8-羧酸戊酯、替莫唑胺-8-羧酸正己酯、替莫唑胺-8-羧酸庚酯、替莫唑胺-8-羧酸辛酯;优选为替莫唑胺-8-羧酸正己酯。
其制备方法如下:
替莫唑胺与浓硫酸混合搅拌。将亚硝酸钠溶解在水中,然后在冰浴15℃以下滴加入反应混合物中,室温搅拌过夜。反应混合物中加入冰,冰浴冷却1小时,过滤收集产品固体替莫唑胺酸,真空干燥。
将无水DMF和无水THF注射进-个盛有替莫唑胺酸和Pybrop的烧瓶中,搅拌混合物使固体全部溶解。冰浴下,加入DMAP,然后注射入适量的无水烃醇或者烃巯醇,继续反应半小时,然后室温搅拌过夜。反应完成后,用布氏漏斗过滤悬浮液,母液蒸馏,剩余物中加入冰,然后用乙酸乙酯,萃取产品。合并乙酸乙酯相用无水硫酸镁干燥,旋蒸除乙酸乙酯,剩余物过硅胶柱纯化,蒸除溶剂后得到产物。
所得产物的结构经红外(IR)、1H-NMR、13C-NMR核磁和质谱(MS)确定,符合规定。
本发明的另一目的在于提供上述替莫唑胺-8-羧酸酯的药用组合物及其制备方法。
制剂(剂型)的选择是根据所要达到的效果,活性成分的性质以及患者的年龄、性别及患者病情病态进行设计。处方中除活性成分外一般还包括液体或固体稀释剂、湿润剂、防腐剂、矫味剂及着色剂等。
由于本发明人发现了替莫唑胺-8-羧酸酯良好的透皮吸收特点,所以其最适合制剂之一透皮吸收局部给药制剂。替莫唑胺-8-羧酸酯透皮吸收局部给药的系统设计基本有两种,分别为基质型和储库型。基质型又可分为单片基质(AM)及复合基质(PM)。储库型分为液体储库系统(LRS)及固体储库系统(SSR)两种,由多层粘合剂(MLA)或多层聚合物基质(MLM)的组成。基质型和储库型替莫唑胺-8-羧酸酯透皮吸收局部给药制剂基本包括:底片,聚合物基质,药物储库(即,药物溶液或悬浮液),控速膜,压力敏感粘合剂(PSAs),保护压力敏感粘合剂(PSAs)的释放层。具体分述如下:
固体储库型贴片:储库药物基质是由水相、油相和表面活性剂按不同比例配制形成的透明稳定的微乳及其制剂,分为固体型和液体型储库贴片。其中的固体型储库贴片,可以选择油酸或肉豆蔻酸异丙酯(IPM)作为油相,也可以选择月桂酸、蜂蜡、琼蜡醇、硬脂醇、液体石蜡、凡士林、无水羊毛脂、硬脂酸、棉子油、蓖麻油、亚麻酸等等。
本发明所说的替莫唑胺-8-羧酸酯选自:替莫唑胺-8-羧酸甲酯、替莫唑胺-8-羧酸乙酯、替莫唑胺-8-羧酸丙酯、替莫唑胺-8-羧酸丁酯、替莫唑胺-8-羧酸-1-甲基-丁酯、替莫唑胺-8-羧酸-1-乙基-丁酯、替莫唑胺-8-羧酸-1-乙基-丙酯、替莫唑胺-8-羧酸-1-乙基-戊酯、替莫唑胺-8-羧酸-1-甲基-己酯、替莫唑胺-8-羧酸-1-甲基-己酯、替莫唑胺-8-羧酸-2-甲基-己酯、替莫唑胺-8-羧酸-3-甲基-己酯、替莫唑胺-8-羧酸-4-甲基-己酯、替莫唑胺-8-羧酸-5-甲基-己酯、替莫唑胺-8-羧酸-1-甲基-庚酯、替莫唑胺-8-羧酸-2-甲基-庚酯、替莫唑胺-8-羧酸-3-甲基-庚酯、替莫唑胺-8-羧酸-4-甲基-庚酯、替莫唑胺-8-羧酸-5-甲基-庚酯、替莫唑胺-8-羧酸-6-甲基-庚酯、替莫唑胺-8-羧酸戊酯、替莫唑胺-8-羧酸正己酯、替莫唑胺-8-羧酸庚酯、替莫唑胺-8-羧酸辛酯;优选为替莫唑胺-8-羧酸正己酯。
本发明替莫唑胺-8-羧酸酯固体储库型贴片的油相优选为肉豆蔻酸异丙酯(IPM)或油酸;水相优选为水;表面活性剂优选维生素E TPGS和柠檬酸。
液体储库型控释贴片由不可透过的底片或称“底片”、液体药物、控速膜、压力敏感粘合剂、释放层热合而成。
其中,本发明替莫唑胺-8-羧酸酯液储库型控释贴片所用的各部分结构如下:
底片,即不可透过的底片,一般是指那些具有渗透性或非渗透性的合成聚合物材料,如聚酯、聚乙烯、聚氯乙烯PVDC、聚亚安酯等,可以是天然的聚合物材料,如棉花、羊毛等。本发明中底片选自下列材料:聚氯乙烯、硝化甘油Nitroglycerin Transdermal、聚二甲基硅氧烷,即Nitrodisc、聚乙烯吡咯烷酮、聚乙烯醇,即Nitro-DurI、聚乙烯吡咯烷酮、聚乙烯氧化物复合物、聚乙二醇、聚乙二醇的各类衍生物例如聚乙二醇单甲醚或双甲醚,聚乙二醇琥伯酸酯及其琥伯酸聚乙二醇维生素E混合双酯(VETPGS)等;优选为聚乙烯、聚氯乙烯PVDC、聚亚氨酯或棉花。
控速膜优选为乙烯-醋酸乙烯共聚物膜或聚氨酯膜、乙二醇二乙酸酯膜等均质膜;压力敏感粘合剂一种独特的生物粘合剂,优选为聚硅氧烷压敏胶或聚丙烯酸酯压敏胶。为便于理解,见图2。
本发明的所述的储库型控释贴片可以按照如下步骤进行:
称取适量的替莫唑胺-8-羧酸正己酯,研成细粉;加水相,如水,和油相如油酸等,与表面活性剂,如Vitamin E TPGS等,混合均匀;加入粉碎的药物混合研磨制成微乳,加入控速膜,如乙烯-醋酸乙烯共聚物膜等,和压力敏感粘合剂适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成贴片,即得。
单片粘附基质贴片:单片粘附基质型是药物分散在压敏胶中,压敏胶控制药物释放。此类释药系统的特点是剂型薄,工艺简单,易于工业化。其中本发明组合物的药物粘附基质辅料选自天然聚合物或合成聚合物,包括聚氯乙烯、聚丙烯酸酯、聚二甲基硅氧烷;亲水性的多聚物,包括聚乙烯吡咯烷酮、聚乙烯醇、凝胶制成的水凝胶,即Prostep、聚乙烯吡咯烷酮和聚乙烯氧化物复合物、聚乙二醇和聚乙二醇的各类衍生物,如聚乙二醇单甲醚或双甲醚,聚乙二醇琥伯酸酯及其琥伯酸聚乙二醇维生素E混合双酯(VETPGS);优选为聚丙烯酸酯。
除此之外,本发明药物组合物的另一主要适合制剂之一还包括口服的固体和液体制剂。
固体口服制剂包括片剂、丸剂、分散粉末、胶囊剂和颗粒剂。在这些种固体制剂中,一般替莫唑胺-8-羧酸酯与至少一种惰性稀释剂混合,包括:碳酸钙、淀粉、褐藻酸或乳糖等;此外,处方中还可包括其他辅料,如润滑剂,硬脂酸镁。
替莫唑胺-8-羧酸酯也可以制成口服液体制剂包括乳剂、溶液剂、悬浮液、糖浆。其中的惰性稀释剂常用含有表面活性剂的水性液体或液体石蜡。除了惰性稀释剂外,液体制剂还包括其他佐剂,例如湿润剂和悬浮剂,象聚乙烯吡咯烷酮、甜味剂、矫味剂、香料和防腐剂。
除上述给药途径外,替莫唑胺-8-羧酸酯的另一个主要适合制剂是栓剂,包括阴道和直肠给药的固体栓剂制剂。替莫唑胺-8-羧酸酯的栓剂制剂除包括常规的赋型剂之外还包括生物可降解的聚合物,如聚乳酸PLGA,聚酸酐和聚混合酸酐CPP∶SA,用以实现缓控释效果。
上述替莫唑胺-8-羧酸酯的剂量通常在0.1-200mg/kg体重/天,优选为1-20mg/kg体重/天之间。
下面通过替莫唑胺-8-羧酸甲酯、丁酯、正己酯的体外抑瘤实验,说明本发明的有益效果。
替莫唑胺-8-羧酸酯体外杀伤肿瘤细胞作用
氟尿嘧啶注射液(10ml:0.25g,上海旭东海普药业有限公司产品,批号:000612)选为阳性对照药同替莫唑胺-8-羧酸甲酯、丁酯、正己酯和已知具有抗癌活性的替莫唑胺酸一起做杀伤癌细胞株的实验.癌细胞株包括HCT-8(人结肠癌细胞),A549(人肺癌细胞),MCF-7(人乳腺癌细胞),Bel7402(人肝癌细胞),BGC-823(人胃癌细胞),MV3(人黑色素瘤细胞)。
实验结果表明(详见表1),替莫唑胺-8-羧酸甲酯、丁酯、和替莫唑胺正己酯对所选用的细胞株的IC50多在10-30ug/ml之间,它们之间作用差别不明显。
表1.MTT法人癌细胞杀伤实验结果
细胞株 | IC50 | ||||
氟尿嘧啶 | 替莫唑胺酸 | 替莫唑胺-8-羧酸正己酯 | 替莫唑胺-8-羧酸甲酯 | 替莫唑胺-8-羧酸丁酯 | |
MV3MCF-7Bel-7402A549HCT-8BGC-823 | 0.4270.6290.4950.1260.6060.722 | 14.62514.91116.957>19.518.525>19.5 | 8.83519.99527.20326.63228.644>19.5 | 8.82717.66525.30427.00128.369>19.5 | 7.56816.55824.36825.33627.359>19.5 |
替莫唑胺-8-羧酸丁酯局部涂抹药物对人黑色素瘤MV3裸小鼠异种移植瘤生长影响
以替莫唑胺-8-羧酸丁酯为代表考察替莫唑胺-8-羧酸酯系列化合物对人黑色素瘤MV3裸小鼠异种移植瘤生长影响。
替莫唑胺-8-羧酸丁酯溶解于二甲基亚砜(DMSO),制成50mg/ml溶液。BALB/c-nu裸小鼠接种人黑色素瘤MV3裸鼠异种移植瘤,待肿瘤体积生长至100-300mm3时将动物按肿瘤大小分层分组,每组8只小鼠。
将其中1组小鼠作为给药组,涂抹替莫唑胺-8-羧酸丁酯溶液,另1组小鼠肿瘤自然生长作为对照。
每日2次(周六、周日为1次)在给药组小鼠肿瘤部位及周围约2×2cm2范围内涂抹药液,每次均在药液干燥后重复涂抹1-2遍。每只小鼠平均每日接受替莫唑胺-8-羧酸丁酯剂量约20mg许。
每周2次测量动物肿瘤体积,动态观察、记录肿瘤生长情况。待对照组肿瘤生长至一定体积,处死动物,剥瘤肿瘤,称瘤重,计算给药组肿瘤生长抑制率,用2组肿瘤相对体积计算相对肿瘤增殖(%T/C)。
结果我们可见,涂抹替莫唑胺-8-羧酸丁酯对荷瘤小鼠生长显示明显抑制作用。替莫唑胺-8-羧酸丁酯对人黑色素瘤MV3等肿瘤细胞具较强的杀伤作用,外用涂抹,每只鼠每日约20mg剂量对移植性肿瘤生长显示抑制作用,实验结束时肿瘤重量与肿瘤体积均与对照组显示明显统计学差别。详见图1两组实验小鼠实体照片和表2。
表2替莫唑胺-8羧酸丁酯涂抹荷MV3裸小鼠肿瘤生长影响(约20mg/只/日)
组别 | 动物数 | 体重(g) | 肿瘤体积(mm3) | RTV | T/C(%) | 瘤重(g) | 抑制率(%) | |||
开始 | 结束 | 开始 | 结束 | 开始 | 结束 | |||||
阴性对照 | 8 | 8 | 22.6±1.56 | 24.8±0.535 | 106±56.3 | 2456±960.3 | 9.35±7.88 | 2.15±0.8.6 | ||
替莫唑胺-8-羧酸丁酯组 | 8 | 8 | 24.0±1.48 | 25.6±3.64 | 115±36 | 635±545.1* | 3.25±1.85 | 33.7 | 0.45±0.335 | 83.2 |
*P<0.05与阴性对照组比较,体重、瘤重、瘤体积以X±SD表示
附图说明
图1两组实验小鼠实体照片
图2适合替莫唑胺酸酯透皮吸收局部给药的基质型和储库型系统图解
具体实施方式
实施例1替莫唑胺酸的合成(EP0252682)
替莫唑胺(2.577mmol,0.5g)与4毫升浓硫酸混合搅拌。将亚硝酸钠(9.4mmol,0.65g)溶解在2.6毫升水中,然后在冰浴15℃以下滴加入反应混合物中,室温搅拌过夜。反应混合物中加入10克冰,冰浴冷却1小时,过滤收集产品固体替莫唑胺酸,真空干燥,得0.493克,收率98.6%。
实施例2替莫唑胺-8-羧酸酯的合成
将无水DMF(2毫升)和无水THF(3毫升)注射进一个盛有替莫唑胺酸(1mmol,0.195g)和Pybrop(1mmol,0.466g)的烧瓶中,搅拌混合物使固体全部溶解。冰浴下,加入DMAP(2mmol,0.244g),然后注射入适量的无水烃醇或者烃巯醇(2.2mmol),继续反应半小时,然后室温搅拌过夜。反应完成后,用布氏漏斗过滤悬浮液,母液蒸馏,剩余物中加入冰(10克),然后用乙酸乙酯(10mL×3)萃取产品。合并乙酸乙酯相用无水硫酸镁干燥,旋蒸除乙酸乙酯,剩余物过硅胶柱纯化,蒸除溶剂后得到产物。
所得产物的结构经红外(IR)、1H-NMR、13C-NMR核磁和质谱(MS)确定。典型产物的结构数据如下。
1.替莫唑胺-8-羧酸甲酯
1H NMR(d6-DMSO/ppm)δ8.86(s,1,H-6),3.90(s,3,CH3-O),3.87(s,3,CH3-N)13C NMR(d6-DMSO/ppm)δ161(COO),139(C-4),137(C-6),129(C-9),126(C-8),52.2(OCH2),36.4(NCH3)
vmax(KBr):3489,2961(C-H),1752(C=O),1727(C=O),1214(C-O),1062(C-O),828,556cm-1
MS:+ES:m/z=232[M+H]+,214[M+H-H2O]+
2.替莫唑胺-8-羧酸乙酯
1H NMR(CDCl3/ppm)δ8.45(s,1,H-6),4.52(q,2,J=7.1Hz,CH2-O),4.04(s,3,CH3-N),1.45(t,3,J=7.1Hz,CH2-CH3)
13C NMR(d6-DMSO/ppm)δ161(COO),139(C-4),137(C-6),129(C-9),127(C-8),60.9(OCH2),36.4(NCH3),14.3(CH2CH3)
vmax(KBr):3478,2991(C-H),1754(C=O),1700(C=O),1467(C-O),1258(C-O),1060(C-O),844,561cm-1
MS:+ES:m/z=246[M+H]+,228[M+H-H2O]+
3.替莫唑胺-8-羧酸丙酯
1H NMR(CDCl3/ppm)δ8.46(s,1,H-6),4.41(t,2,J=6.7Hz,CH2-O),4.03(s,3,CH3-N),1.83(sextet,2,J=7.1Hz,C-CH2-C),1.03(t,3,J=7.4Hz,C-CH3)
13C NMR(CDCl3/ppm)δ160(COO),138(C-4),136(C-6),130(C-9),128(C-8),67.1(OCH2),36.5(NCH3),21.7(CH2CH3),8.87(CH2CH3)
vmax(KBr):3122,2960(C-H),1729(C=O),1700(C=O),1457(C-O),1200(C-O),1174(C-O),1052,942cm-1
MS:+ES:m/z=260[M+H]+,242[M+H-H2O]+
4.替莫唑胺-8-羧酸丁酯
1H NMR(CDCl3/ppm)δ8.45(s,1H-6),4.45(t,2,J=7.1Hz,CH2-O),4.03(s,3,CH3-N),1.79(quintet,2,J=7.4Hz,C-CH2-C),1.46(sextet,2,J=7.3Hz,C-CH2-CH3),0.95(t,3,J=7.3Hz,C-CH3)
13C NMR(d6-DMSO/ppm)δ161(COO),139(C-4),137(C-6),129(C-9),127(C-8),64.5(OCH2),36.4(NCH3),30.3(OCH2CH2),18.7(CH2CH3),13.6(CH2CH3)
vmax(KBr):3156,2967(C-H),1746(C=O),1467(C-O),1261(C-O),1054(C-O),823,561cm-1
MS:+ES:m/z=274[M+H]+,256[M+H-H2O]+
5.替莫唑胺-8-羧酸戊酯
1H NMR(CDCl3/ppm)δ8.46(s,1,H-6),4.45(t,2,J=7.0Hz,CH2-O),4.03(s,3,CH3-N),1.79(quintet,2,J=7.1Hz,C-CH2-C),1.29-1.40(m,4,C-(CH2)2-CH3),0.96(t,3,J=6.9Hz,C-CH3)
13CMR(d6-DMSO/ppm)δ161(COO),139(C-4),137(C-6),129(C-9),127(C-8),64.6(OCH2),36.4(NCH3),30.9(OCH2CH2),28.2(O(CH2)2CH2),22.8(CH2CH3),14.0(CH2CH3)
vax(KBr):3136,2967(C-H),1736(C=O),1459(C-O),1231(C-O),1154(C-O),923,761cm1
MS:+ES:m/z=288[M+H]+,270[M+H-H2O]+
6.替莫唑胺-8-羧酸己酯
1H NMR(CDCl3/ppm)δ8.49(s,1,H-6),4.45(t,2,J=6.9Hz,CH2-O),4.04(s,3,CH3-N),1.79(quintet,2,J=7.1Hz,C-CH2-C),1.29-1.40(m,6,C(CH2)3-CH3),0.87(t,3,J=6.9Hz,C-CH3)
13CMR(d6-DMSO/ppm)δ161(COO),139(C-4),137(C-6),129(C-9),127(C-8),64.8(OCH2),36.4(NCH3),30.9(OCH2CH2),28.2(O(CH2)2CH2),25.1(CH2CH2CH3),22.1(CH2CH3),13.9(CH2CH3)
vmax(KBr):3156,2967(C-H),1746(C=O),1467(C-O),1261(C-O),1054(C-O),823,561cm-1
MS:+ES:m/z=302[M+H]+,284[M+H-H2O]+
7.替莫唑胺-8-羧酸庚酯
1H NMR(CDCl3/ppm)δ8.39(s,1,H-6),4.38(s,2,CH2-O),4.00(s,3,CH3-N),1.75(s,2,C-CH3-C),1.19(s,8,C-(CH2)4-C),0.83(s,3,C-CH3)
13C NMR(d6-DMSO/ppm)δ161(COO),139(C-4),137(C-6),129(C-9),127(C-8),64.8(OCH2),36.4(NCH3),31.1(OCH2CH2),2X28.4(OCH2CH2(CH2)2),25.3(CH2CH2CH3),22.1(CH2CH3),13.8(CH2CH3)
vmax(KBr):3146,2927(C-H),2858(C-H),1748(C=O),1718(C=O),1457(C-O),1245(C-O),828,566cm-1
MS:+ES:m/z=316[M+H]+,398[M+H-H2O]+
8.替莫唑胺-8-羧酸辛酯
1H NMR(CDCl3/ppm)δ8.36(s,1,H-6),4.36(s,2,CH2-O),3.95(s,3,CH3-N),1.74(s,2,C-CH3-C),1.19(s,10,C-(CH2)5-C),0.78(s,3,C-CH3)
13C NMR(d6-DMSO/ppm)δ160(COO),139(C-4),137(C-6),129(C-9),127(C-8),64.8(OCH2),36.4(NCH3),31.2(OCH2CH2),2X28.6(OCH2CH2(CH2)2),28.2(O(CH2)1CH2),25.4(CH2CH2CH3),22.1(CH2CH3),13.9(CH2CH3)
vmax(KBr):2925,2853,1758,1720,1467,1255,838,556cm-1
MS:+ES:m/z=330[M+H]+,312[M+H-H2O]+
实施例3替莫唑胺-8-羧酸甲酯固体储库系统的制备
称取3g的替莫唑胺-8-羧酸甲酯,研成细粉;取20g水、50g油酸,30gVitamin E TPGS和适量的柠檬酸,加入粉碎的药物混合研磨制成微乳,加入控速膜乙烯-醋酸乙烯共聚物膜,和压力敏感粘合剂聚硅氧烷压敏胶适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成50个贴片,即得。
实施例4替莫唑胺-8-羧酸丙酯固体储库系统的制备
称取3g的替莫唑胺-8-羧酸丙酯,研成细粉;取20g水、50g油酸,30gVitamin E TPGS和适量的柠檬酸,加入粉碎的药物混合研磨制成微乳,加入控速膜乙烯-醋酸乙烯共聚物膜,和压力敏感粘合剂聚硅氧烷压敏胶适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成50个贴片,即得。
实施例5替莫唑胺-8-羧酸丁酯固体储库系统的制备
称取3g的替莫唑胺-8-羧酸丁酯,研成细粉;取20g水、50g油酸,30gVitamin E TPGS和适量的柠檬酸,加入粉碎的药物混合研磨制成微乳,加入控速膜乙烯-醋酸乙烯共聚物膜,和压力敏感粘合剂聚硅氧烷压敏胶适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成50个贴片,即得。
实施例6替莫唑胺-8-羧酸庚酯固体储库系统的制备
称取3g的替莫唑胺-8-羧酸庚酯,研成细粉;取20g水、50g油酸,30gVitamin E TPGS和适量的柠檬酸,加入粉碎的药物混合研磨制成微乳,加入控速膜乙烯-醋酸乙烯共聚物膜,和压力敏感粘合剂聚硅氧烷压敏胶适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成50个贴片,即得。
实施例7替莫唑胺-8-羧酸正己酯固体储库系统的制备
称取3g的替莫唑胺-8-羧酸正己酯,研成细粉;取20g水、50g油酸,30gVitamin E TPGS和适量的柠檬酸,加入粉碎的药物混合研磨制成微乳,加入控速膜乙烯-醋酸乙烯共聚物膜,和压力敏感粘合剂聚硅氧烷压敏胶适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成50个贴片,即得。
实施例8替莫唑胺-8-羧酸乙酯固体储库系统的制备
称取3g的替莫唑胺-8-羧酸乙酯,研成细粉;取20g水、50g油酸,30gVitamin E TPGS和适量的柠檬酸,加入粉碎的药物混合研磨制成微乳,加入控速膜乙烯-醋酸乙烯共聚物膜,和压力敏感粘合剂聚硅氧烷压敏胶适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成50个贴片,即得。
实施例9替莫唑胺-8-羧酸丁酯固体储库系统的制备
称取3g的替莫唑胺-8-羧酸丁酯,研成细粉;取20g水、50g油酸,30gVitamin E TPGS和适量的柠檬酸,加入粉碎的药物混合研磨制成微乳,加入控速膜乙烯-醋酸乙烯共聚物膜,和压力敏感粘合剂聚硅氧烷压敏胶适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成50个贴片,即得。
实施例10替莫唑胺-8-羧酸丁酯制剂的制备
将替莫唑胺-8-羧酸丁酯研成细粉,然后装入盛有5mg胶囊中,制成胶囊制剂。
实施例11替莫唑胺-8-羧酸庚酯制剂的制备
将替莫唑胺-8-羧酸庚酯研成细粉,然后装入盛有10mg胶囊中,制成胶囊制剂。
实施例12替莫唑胺-8-羧酸辛酯制剂的制备
将替莫唑胺-8-羧酸辛酯研成细粉,然后装入盛有10mg胶囊中,制成胶囊制剂。
实施例13替莫唑胺-8-羧酸正己酯制剂的制备
处方:替莫唑胺-8-羧酸正己酯 3g
水 20g
油酸 50g
维生素E TPGS 30g
柠檬酸 适量
按处方量将上述物质混合制成微乳,加入控速膜乙烯-醋酸乙烯共聚物膜,和压力敏感粘合剂聚硅氧烷压敏胶适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成50个贴片,即得。
实施例14替莫唑胺-8-羧酸甲酯制剂的制备
处方:替莫唑胺-8-羧酸甲酯 3g
水 20g
油酸 50g
维生素E TPGS 30g
柠檬酸 适量
按处方量将上述物质混合制成微乳,加入控速膜乙烯-醋酸乙烯共聚物膜,和压力敏感粘合剂聚硅氧烷压敏胶适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成50个贴片,即得。
实施例15替莫唑胺-8-羧庚酯制剂的制备
处方:
替莫唑胺-8-羧酸庚酯 4.8%
聚丙烯酸酯 32.2%
柠檬酸三乙酯 3.0%
丙酮 60%
按处方量将上述物质混合,挥发溶剂后制成含药压敏胶层。
实施例16替莫唑胺-8-羧戊酯制剂的制备
处方:
替莫唑胺-8-羧酸戊酯 4.8%
聚丙烯酸酯 32.2%
柠檬酸三乙酯 3.0%
丙酮 60%
按处方量将上述物质混合,挥发溶剂后制成含药压敏胶层。
实施例17替莫唑胺-8-羧酸酯制剂的制备
替莫唑胺-8-羧酸正己酯 10mg
乳糖 65mg
预胶化淀粉 25mg
交联羧甲基纤维素钠 3mg
微粉硅胶 0.25mg
硬酯酸镁 0.30mg
将替莫唑胺-8-羧酸正己酯、乳糖、预胶化淀粉、交联羧甲基纤维素钠分别过65目筛备用。按处方量的替莫唑胺-8-羧酸正己酯,按等量递加法与其他辅料混合均匀,过65目筛3次;测休止角,小于30°;测含量,定装量;将该粉末装3号胶囊。
实施例18替莫唑胺-8-羧酸辛酯制剂的制备
替莫唑胺-8-羧酸辛酯 10mg
乳糖 65mg
预胶化淀粉 25mg
交联羧甲基纤维素钠 3mg
微粉硅胶 0.25mg
硬酯酸镁 0.30mg
将替莫唑胺-8-羧酸辛酯、乳糖、预胶化淀粉、交联羧甲基纤维素钠分别过65目筛备用。按处方量的替莫唑胺-8-羧酸正己酯,按等量递加法与其他辅料混合均匀,过65目筛3次;测休止角,小于30°;测含量,定装量;将该粉末装3号胶囊。
实施例19替莫唑胺-8-羧酸-3-甲基-庚酯制剂的制备
替莫唑胺-8-羧酸-3-甲基-庚酯 10mg
乳糖 65mg
预胶化淀粉 25mg
交联羧甲基纤维素钠 3mg
微粉硅胶 0.25mg
硬酯酸镁 0.30mg
将替莫唑胺-8-羧酸-3-甲基-庚酯、乳糖、预胶化淀粉、交联羧甲基纤维素钠分别过65目筛备用。按处方量的替莫唑胺-8-羧酸正己酯,按等量递加法与其他辅料混合均匀,过65目筛3次;测休止角,小于30°;测含量,定装量;将该粉末装3号胶囊。
实施例20替莫唑胺-8-羧酸-2-乙基-戊酯制剂的制备
处方:替莫唑胺-8-羧酸-2-乙基-戊酯 3g
水 20g
油酸 50g
维生素E TPGS 30g
柠檬酸 适量
按处方量将上述物质混合制成微乳,加入控速膜乙烯-醋酸乙烯共聚物膜,和压力敏感粘合剂聚硅氧烷压敏胶适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成50个贴片,即得。
Claims (19)
2.权利要求1所述的替莫唑胺-8-羧酸酯,其中的替莫唑胺-8-羧酸酯为替莫唑胺-8-羧酸甲酯、替莫唑胺-8-羧酸乙酯、替莫唑胺-8-羧酸丙酯、替莫唑胺-8-羧酸丁酯、替莫唑胺-8-羧酸-1-甲基-丁酯、替莫唑胺-8-羧酸-1-乙基-丁酯、替莫唑胺-8-羧酸-1-乙基-丙酯、替莫唑胺-8-羧酸-1-乙基-戊酯、替莫唑胺-8-羧酸-1-甲基-己酯、替莫唑胺-8-羧酸-1-甲基-己酯、替莫唑胺-8-羧酸-2-甲基-己酯、替莫唑胺-8-羧酸-3-甲基-己酯、替莫唑胺-8-羧酸4-甲基-己酯、替莫唑胺-8-羧酸-5-甲基-己酯、替莫唑胺-8-羧酸-1-甲基-庚酯、替莫唑胺-8-羧酸-2-甲基-庚酯、替莫唑胺-8-羧酸-3-甲基-庚酯、替莫唑胺-8-羧酸-4-甲基-庚酯、替莫唑胺-8-羧酸-5-甲基-庚酯、替莫唑胺-8-羧酸-6-甲基-庚酯、替莫唑胺-8-羧酸戊酯、替莫唑胺-8-羧酸正己酯、替莫唑胺-8-羧酸庚酯、替莫唑胺-8-羧酸辛酯。
3.权利要求1所述的替莫唑胺-8-羧酸酯,其中的替莫唑胺-8-羧酸酯为替莫唑胺-8-羧酸正己酯。
4.一种药物组合物,包括药用辅料和权利要求1所述的化合物为活性成分。
5.权利要求4所述的组合物,其中的活性成分具体为替莫唑胺-8-羧酸正己酯。
6.权利要求4所述的组合物,其中的活性成分按照0.1-200mg/kg体重/天的剂量施与患者。
7.权利要求6所述的组合物,其中的剂量为1-20mg/kg体重/天。
8.权利要求4-7中任意组合物,其中所述组合物可以制成药剂学上任何一种剂型。
9.权利要求8所述的组合物,其中所述剂型为局部透皮贴剂。
10.权利要求9所述的组合物,其中的局部透皮贴剂为基质型控释贴剂、固体储库型控释贴剂或液体储库型控释贴剂。
11.权利要求8或9所述的组合物,其中的固体储库型控释贴剂中的水相为水,油相选自油酸、肉豆蔻酸异丙酯、月桂酸、蜂蜡、琼蜡醇、硬脂醇、液体石蜡、凡士林、无水羊毛脂、硬脂酸、棉子油、蓖麻油、亚麻酸。
12.权利要求11所述的组合物,其中的油相为油酸或肉豆蔻酸异丙酯。
13.权利要求9或10所述的组合物,其中的液体储库型控释贴剂由不可透过的底片、液体药物、控速膜、压力敏感粘合剂以及释放层组成其中,
底片,选自选自聚乙烯、聚氯乙烯、硝化甘油、聚二甲基硅氧烷、聚乙烯吡咯烷酮、聚乙烯醇、聚乙烯吡咯烷酮、聚乙烯氧化物复合物、聚乙二醇、聚乙二醇单甲醚或双甲醚,聚乙二醇琥伯酸酯及其琥伯酸聚乙二醇维生素E混合双酯、羊毛、棉花;
控速膜选自乙烯-醋酸乙烯共聚物膜或聚氨酯膜、乙二醇二乙酸酯膜;
压力敏感粘合剂选自聚硅氧烷压敏胶或聚丙烯酸酯压敏胶。
14.权利要求13所述的组合物,其中所述的底片为聚乙烯、聚氯乙烯。
15.权利要求13所述的组合物,其中的基质型控释贴剂中药物粘附基质辅料选自聚氯乙烯、聚丙烯酸酯、聚二甲基硅氧烷、聚乙烯吡咯烷酮、聚乙烯醇、凝胶制成的水凝胶、聚乙烯吡咯烷酮和聚乙烯氧化物复合物、聚乙二醇单甲醚或双甲醚、聚乙二醇琥伯酸酯及其琥伯酸聚乙二醇维生素E混合双酯。
16.权利要求13所述的组合物,其中的药物粘附基质辅料为聚丙烯酸酯。
17.权利要求8所述的组合物,其中的剂型为片剂、丸剂、分散粉末、胶囊剂、颗粒剂、乳剂、溶液剂、悬浮液、糖浆、阴道或直肠给药的固体栓剂制剂。
18.上述4所述组合物的制备方法,包括如下步骤:
称取适量的权利要求1所述的替莫唑胺-8-羧酸酯为活性成分,研成细粉;加入水相和油相和表面活性剂等,混合均匀;加入粉碎的药物混合研磨制成微乳,加入控速膜和压力敏感粘合剂适量,搅匀,水浴保温脱气,涂膜于聚乙烯底片上,烘干,切成贴片,即得。
19.上述4或6所述组合物制备的储库型控释贴片。
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2004100720564A CN1752088A (zh) | 2004-09-22 | 2004-09-22 | 含有替莫唑胺酯的药用组合物 |
EP05785075A EP1798234B1 (en) | 2004-09-22 | 2005-09-15 | Pharmaceutical composition comprising temozolomide ester |
AU2005287799A AU2005287799B2 (en) | 2004-09-22 | 2005-09-15 | Pharmaceutical composition comprising temozolomide ester |
NZ554609A NZ554609A (en) | 2004-09-22 | 2005-09-15 | Pharmaceutical composition comprising temozolomide ester |
BRPI0515555-0A BRPI0515555A (pt) | 2004-09-22 | 2005-09-15 | composição farmacêutica compreendendo éster de temozolomida |
PCT/CN2005/001477 WO2006032190A1 (fr) | 2004-09-22 | 2005-09-15 | Composition pharmaceutique comprenant un ester de temozolomide |
US11/575,849 US7579336B2 (en) | 2004-09-22 | 2005-09-15 | Pharmaceutical composition comprising temozolomide ester |
CA2580910A CA2580910C (en) | 2004-09-22 | 2005-09-15 | Pharmaceutical composition comprising temozolomide ester |
ES05785075T ES2389376T3 (es) | 2004-09-22 | 2005-09-15 | Composición farmacéutica que comprende ester de temozolomida |
KR1020077009054A KR101065984B1 (ko) | 2004-09-22 | 2005-09-15 | 테모졸로마이드 에스테르를 포함하는 약학 조성물 |
MX2007003366A MX2007003366A (es) | 2004-09-22 | 2005-09-15 | Composicion farmaceutica que comprende un ester de temozolomida. |
DK05785075.2T DK1798234T3 (da) | 2004-09-22 | 2005-09-15 | Farmaceutisk sammensætning omfattende temozolomidester |
JP2007532748A JP5620046B2 (ja) | 2004-09-22 | 2005-09-15 | テモゾロマイドエステルよりなる医薬組成物 |
UAA200704418A UA89795C2 (ru) | 2004-09-22 | 2005-09-15 | Фармацевтическая композиция, которая содержит эстер темозоломида |
PL05785075T PL1798234T3 (pl) | 2004-09-22 | 2005-09-15 | Kompozycja farmaceutyczna zawierająca ester temozolomidu |
RU2007114948/04A RU2393160C2 (ru) | 2004-09-22 | 2005-09-15 | Фармацевтическая композиция, содержащая эфир темозоломида |
ARP050103949A AR050947A1 (es) | 2004-09-22 | 2005-09-21 | Derivados de 3,4-dihidro-3-metil-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazina-8-carboxilato |
MYPI20054428A MY153713A (en) | 2004-09-22 | 2005-09-22 | A pharmaceutical composition comprising 3, 4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-1,2,3,5-tetrazine-8-carboxylate |
IL182027A IL182027A (en) | 2004-09-22 | 2007-03-19 | Pharmaceutical composition comprising tamoxolomide ester and the method of preparation thereof |
ZA200702801A ZA200702801B (en) | 2004-09-22 | 2007-04-03 | Pharmaceutical composition comprising temozolomide ester |
HK07108352.8A HK1100440A1 (en) | 2004-09-22 | 2007-07-31 | Pharmaceutical composition comprising temozolomide ester |
JP2012209183A JP2013028630A (ja) | 2004-09-22 | 2012-09-24 | テモゾロマイドエステルよりなる医薬組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2004100720564A CN1752088A (zh) | 2004-09-22 | 2004-09-22 | 含有替莫唑胺酯的药用组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1752088A true CN1752088A (zh) | 2006-03-29 |
Family
ID=36089840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100720564A Pending CN1752088A (zh) | 2004-09-22 | 2004-09-22 | 含有替莫唑胺酯的药用组合物 |
Country Status (21)
Country | Link |
---|---|
US (1) | US7579336B2 (zh) |
EP (1) | EP1798234B1 (zh) |
JP (2) | JP5620046B2 (zh) |
KR (1) | KR101065984B1 (zh) |
CN (1) | CN1752088A (zh) |
AR (1) | AR050947A1 (zh) |
AU (1) | AU2005287799B2 (zh) |
BR (1) | BRPI0515555A (zh) |
CA (1) | CA2580910C (zh) |
DK (1) | DK1798234T3 (zh) |
ES (1) | ES2389376T3 (zh) |
HK (1) | HK1100440A1 (zh) |
IL (1) | IL182027A (zh) |
MX (1) | MX2007003366A (zh) |
MY (1) | MY153713A (zh) |
NZ (1) | NZ554609A (zh) |
PL (1) | PL1798234T3 (zh) |
RU (1) | RU2393160C2 (zh) |
UA (1) | UA89795C2 (zh) |
WO (1) | WO2006032190A1 (zh) |
ZA (1) | ZA200702801B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1727340B (zh) * | 2004-07-29 | 2011-05-18 | 天津帝士力投资控股集团有限公司 | 一种替莫唑胺-8-羧酸酯及其组合物 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1808173A1 (en) * | 2006-01-12 | 2007-07-18 | Matthias Dormeyer | Use of CNS penetrating anticancer compounds for the treatment of protozan diseases |
US8558511B2 (en) * | 2009-04-07 | 2013-10-15 | Battelle Memorial Institute | Method and apparatus for smart battery charging including a plurality of controllers each monitoring input variables |
KR20140087846A (ko) * | 2012-12-31 | 2014-07-09 | 주식회사 삼양바이오팜 | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 |
RU2527258C1 (ru) * | 2013-02-19 | 2014-08-27 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | 6-ЗАМЕЩЕННЫЕ 3-АЗОЛИЛИМИДАЗО[1,2-b][1,2,4,5]ТЕТРАЗИНЫ, ПРОЯВЛЯЮЩИЕ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ |
US10709715B2 (en) * | 2017-12-03 | 2020-07-14 | Cipla Limited | Method of treating hypertension |
CN114014862A (zh) * | 2021-06-28 | 2022-02-08 | 烟台大学 | 一种治疗脑胶质瘤的新化合物及其制备和应用 |
CN115260107B (zh) * | 2022-06-23 | 2023-11-24 | 烟台邦杰生物科技有限公司 | 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8616125D0 (en) * | 1986-07-02 | 1986-08-06 | May & Baker Ltd | Compositions of matter |
CN1244583C (zh) * | 2002-09-29 | 2006-03-08 | 天津天士力集团有限公司 | 替莫唑胺-8-羧酸脂和-8-酰胺衍生物,它们的合成方法以及它们在制备抗癌制剂中的应用 |
CN1742723A (zh) * | 2004-09-02 | 2006-03-08 | 天津倍方科技发展有限公司 | 含有替莫唑胺-8-羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途 |
-
2004
- 2004-09-22 CN CNA2004100720564A patent/CN1752088A/zh active Pending
-
2005
- 2005-09-15 RU RU2007114948/04A patent/RU2393160C2/ru not_active IP Right Cessation
- 2005-09-15 AU AU2005287799A patent/AU2005287799B2/en not_active Ceased
- 2005-09-15 JP JP2007532748A patent/JP5620046B2/ja not_active Expired - Fee Related
- 2005-09-15 US US11/575,849 patent/US7579336B2/en not_active Expired - Fee Related
- 2005-09-15 NZ NZ554609A patent/NZ554609A/en not_active IP Right Cessation
- 2005-09-15 UA UAA200704418A patent/UA89795C2/ru unknown
- 2005-09-15 BR BRPI0515555-0A patent/BRPI0515555A/pt not_active IP Right Cessation
- 2005-09-15 PL PL05785075T patent/PL1798234T3/pl unknown
- 2005-09-15 DK DK05785075.2T patent/DK1798234T3/da active
- 2005-09-15 ES ES05785075T patent/ES2389376T3/es active Active
- 2005-09-15 WO PCT/CN2005/001477 patent/WO2006032190A1/zh active Application Filing
- 2005-09-15 CA CA2580910A patent/CA2580910C/en not_active Expired - Fee Related
- 2005-09-15 MX MX2007003366A patent/MX2007003366A/es active IP Right Grant
- 2005-09-15 EP EP05785075A patent/EP1798234B1/en not_active Not-in-force
- 2005-09-15 KR KR1020077009054A patent/KR101065984B1/ko not_active IP Right Cessation
- 2005-09-21 AR ARP050103949A patent/AR050947A1/es not_active Application Discontinuation
- 2005-09-22 MY MYPI20054428A patent/MY153713A/en unknown
-
2007
- 2007-03-19 IL IL182027A patent/IL182027A/en not_active IP Right Cessation
- 2007-04-03 ZA ZA200702801A patent/ZA200702801B/xx unknown
- 2007-07-31 HK HK07108352.8A patent/HK1100440A1/xx not_active IP Right Cessation
-
2012
- 2012-09-24 JP JP2012209183A patent/JP2013028630A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1727340B (zh) * | 2004-07-29 | 2011-05-18 | 天津帝士力投资控股集团有限公司 | 一种替莫唑胺-8-羧酸酯及其组合物 |
Also Published As
Publication number | Publication date |
---|---|
JP2008513523A (ja) | 2008-05-01 |
MX2007003366A (es) | 2008-03-05 |
EP1798234B1 (en) | 2012-06-13 |
BRPI0515555A (pt) | 2008-07-29 |
JP5620046B2 (ja) | 2014-11-05 |
RU2393160C2 (ru) | 2010-06-27 |
AU2005287799B2 (en) | 2009-03-26 |
EP1798234A4 (en) | 2009-04-29 |
IL182027A0 (en) | 2007-07-24 |
NZ554609A (en) | 2010-06-25 |
KR20070062569A (ko) | 2007-06-15 |
DK1798234T3 (da) | 2012-08-27 |
US20080044457A1 (en) | 2008-02-21 |
KR101065984B1 (ko) | 2011-09-19 |
WO2006032190A1 (fr) | 2006-03-30 |
JP2013028630A (ja) | 2013-02-07 |
ZA200702801B (en) | 2008-08-27 |
ES2389376T3 (es) | 2012-10-25 |
US7579336B2 (en) | 2009-08-25 |
RU2007114948A (ru) | 2008-10-27 |
EP1798234A1 (en) | 2007-06-20 |
PL1798234T3 (pl) | 2012-11-30 |
IL182027A (en) | 2014-05-28 |
UA89795C2 (ru) | 2010-03-10 |
MY153713A (en) | 2015-03-13 |
CA2580910A1 (en) | 2006-03-30 |
AU2005287799A1 (en) | 2006-03-30 |
AR050947A1 (es) | 2006-12-06 |
CA2580910C (en) | 2011-10-25 |
HK1100440A1 (en) | 2007-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1694867A (zh) | 口服固体药用晶体及治疗排尿困难的包含它的口服固体药 | |
EA025407B1 (ru) | Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она | |
CN1216869C (zh) | 赛利可喜的多态晶型 | |
CN1219131A (zh) | 作为tnf抑制剂和pdc-iv抑制剂的喹啉甲酰胺类化合物 | |
CN1703204A (zh) | 含有碱性赋形剂的稳定的药物组合物 | |
CN112745323B (zh) | 枸橼酸爱地那非晶型h及其制备方法和用途 | |
JP2013028630A (ja) | テモゾロマイドエステルよりなる医薬組成物 | |
CN1724529A (zh) | 高纯度蛇床子素及其制备方法和以该化合物为活性成分的药物组合物 | |
CN1761665A (zh) | 抗肿瘤效果增强剂和抗肿瘤剂 | |
CN1031827C (zh) | 取代的苯并咪唑的制备方法 | |
CN1727340A (zh) | 一种替莫唑胺-8-羧酸酯及其组合物 | |
CN103864765B (zh) | 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途 | |
CN101029034A (zh) | 多烯紫杉醇水溶性衍生物及制备方法和用途 | |
CN1732913A (zh) | 一种稳定性好的棓丙酯注射液及其制备方法 | |
CN102786458B (zh) | 吡咯甲酰胺衍生物、其制备方法和用途 | |
CN1742723A (zh) | 含有替莫唑胺-8-羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途 | |
CN1319971C (zh) | 喜树碱衍生物及其用途 | |
CN107200719B (zh) | 990207-22-1一种晶vii型物质、其制法和其药物组合物与用途 | |
CN1199946C (zh) | 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用 | |
CN100339377C (zh) | 喜树碱衍生物及其制备 | |
CN101033211A (zh) | 5-氯-4-羟基-2(1h)-吡啶酮晶型及其制备方法和应用 | |
CN1098258C (zh) | 异香豆素衍生物及其在医药上的应用 | |
CN107200720B (zh) | 一种晶ⅱ型物质、其制法和其药物组合物与用途 | |
CN109721557A (zh) | 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途 | |
CN101973987B (zh) | 埃博霉素类似物,制备方法及其药物组合物和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |